1. Home
  2. BLLN vs TMDX Comparison

BLLN vs TMDX Comparison

Compare BLLN & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BLLN

BillionToOne Inc.

N/A

Current Price

$77.00

Market Cap

3.9B

Sector

Health Care

ML Signal

N/A

Logo TransMedics Group Inc.

TMDX

TransMedics Group Inc.

HOLD

Current Price

$100.02

Market Cap

3.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BLLN
TMDX
Founded
2016
1998
Country
United States
United States
Employees
713
N/A
Industry
Medical Specialities
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.9B
3.8B
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
BLLN
TMDX
Price
$77.00
$100.02
Analyst Decision
Buy
Buy
Analyst Count
7
9
Target Price
$126.71
$148.22
AVG Volume (30 Days)
372.4K
807.3K
Earning Date
05-06-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
382.18
EPS
N/A
4.87
Revenue
N/A
$605,494,000.00
Revenue This Year
$46.29
$24.25
Revenue Next Year
$30.14
$18.75
P/E Ratio
N/A
$20.58
Revenue Growth
N/A
37.13
52 Week Low
$61.96
$89.65
52 Week High
$138.70
$156.00

Technical Indicators

Market Signals
Indicator
BLLN
TMDX
Relative Strength Index (RSI) 45.20 38.23
Support Level $64.99 $93.08
Resistance Level $83.20 $120.60
Average True Range (ATR) 6.09 5.24
MACD -1.22 -0.83
Stochastic Oscillator 23.02 12.82

Price Performance

Historical Comparison
BLLN
TMDX

About BLLN BillionToOne Inc.

BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.

About TMDX TransMedics Group Inc.

TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.

Share on Social Networks: